Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Phospholipase C gamma 2 Antibodies:
anti-Rat (Rattus) Phospholipase C gamma 2 Antibodies:
anti-Human Phospholipase C gamma 2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal Phospholipase C gamma 2 Primary Antibody for IHC - ABIN966863
Kim, Sekiya, Poulin, Bae, Rhee: Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. in Molecular and cellular biology 2004
Show all 2 Pubmed References
Human Polyclonal Phospholipase C gamma 2 Primary Antibody for IF (p), IHC (p) - ABIN744848
Diaz-Flores, Goldschmidt, Depeille, Ng, Akutagawa, Krisman, Crone, Burgess, Williams, Houseman, Shokat, Sampath, Bollag, Roose, Braun, Shannon: PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. in Science signaling 2013
Human Monoclonal Phospholipase C gamma 2 Primary Antibody for ICS - ABIN1177150
Holodick, Tumang, Rothstein: Continual signaling is responsible for constitutive ERK phosphorylation in B-1a cells. in Molecular immunology 2009
Syk (show SYK Antibodies)-induced signals in bone marrow stromal cell lines are mediated by phospholipase C (show PLC Antibodies) gamma1 (PLCgamma1 (show PLCG1 Antibodies)) in osteogenesis and PLCgamma2 in adipogenesis.
Results show that mice with the mutated Plcg2 gene were less prone to transformation into MALT lymphomas as a result of elevated Treg numbers, and decrease of pro-inflammatory cytokines.
PLCgamma2 in clear cells plays an essential role in luminal expansion of the epididymis during the prepubertal period in mice
platelet activation through GPVI (show GP6 Antibodies) and alphaIIbbeta3 utilizes PLCgamma2 because PLCgamma1 (show PLCG1 Antibodies) levels are insufficient to support responsiveness, but that PLCgamma1 (show PLCG1 Antibodies) can restore responsiveness if expressed at levels normally achieved by PLCgamma2.
amarogentin prevents platelet activation through the inhibition of PLC (show HSPG2 Antibodies) gamma2-PKC (show PKC Antibodies) cascade and MAPK (show MAPK1 Antibodies) pathway
PLCgamma2 and protein kinase C (show PKC Antibodies) are important upstream signals that regulate myelopoiesis through cytokines.
inflammatory osteolysis can be abrogated by treatment with a molecule composed of the tandem SH2 (show MYO15 Antibodies) domains of PLCgamma2.
down-regulation of PLCgamma2-beta-catenin (show CTNNB1 Antibodies) pathway occurs in mice and humans and leads to myeloid-derived suppressor cells-mediated tumor expansion.
a novel role of the PLCgamma2-IP(3)-Ca(2 (show CA2 Antibodies)+) cascade in the LPS (show TLR4 Antibodies)-induced innate immune response pathway where release of intracellular Ca(2 (show CA2 Antibodies)+) mediates TLR4 (show TLR4 Antibodies) trafficking and subsequent activation of IRF3 (show IRF3 Antibodies).
VapB (show VAPB Antibodies) positively regulates RANKL (show TNFSF11 Antibodies)-mediated osteoclastogenesis via PLCgamma2-Ca(2 (show CA2 Antibodies)+)-NFAT (show NFATC1 Antibodies) signaling
Data show that protein-altering changes are in PLCG2, ABI3 (show ABI3 Antibodies), and TREM2 (show TREM2 Antibodies) genes highly expressed in microglia and highlight an immune-related protein-protein interaction network in Alzheimer's disease.
Ocular manifestations of phospholipase-Cgamma2-associated antibody deficiency and immune dysregulation show mutations in the PLC (show HSPG2 Antibodies)[gamma]2 gene leading to aberrant function of immune cells and overproduction of interleukin-1 [beta] (IL-1 (show IL1A Antibodies)[beta]).
R665W and L845F be referred to as allomorphic rather than hypermorphic mutations of PLCG2 Rerouting of the transmembrane signals emanating from BCR (show BCR Antibodies) and converging on PLCgamma2 through Rac (show AKT1 Antibodies) in ibrutinib-resistant CLL cells may provide novel drug treatment strategies to overcome ibrutinib resistance mediated by PLCG2 mutations or to prevent its development in ibrutinib-treated CLL patients.
Data show that phospholipase Cgamma2 (PLCgamma2) is strongly expressed in B cell non-Hodgkin lymphoma and especially in a large subset of Diffuse large B-cell lymphoma (DLBCL).
Characterization of the effect of missense point-mutation at R665W in PLCG2 on signaling mechanisms of ibrutinib resistance in chronic lymphocytic leukemia cells.
amarogentin prevents platelet activation through the inhibition of PLC (show HSPG2 Antibodies) gamma2-PKC (show PRRT2 Antibodies) cascade and MAPK (show MAPK1 Antibodies) pathway
PLCG2 missense mutation is a risk factor in the development of steroid sensitive nephrotic syndrome in childhood.
The autoinhibitory C-terminal SH2 domain of phospholipase C (show PLC Antibodies)-gamma2 stabilizes B cell receptor signalosome assembly.
The relationship between upstream tyrosine kinase (show TXK Antibodies) SYK (show SYK Antibodies) and its target, PLCgamma2, is maximally predictive and sufficient to distinguish chronic lymphocytic leukemia from healthy controls.
The protein encoded by this gene is a transmembrane signaling enzyme that catalyzes the conversion of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate to 1D-myo-inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), using calcium as a cofactor. IP3 and DAG are second messenger molecules important for transmitting signals from growth factor receptors and immune system receptors across the cell membrane.
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2
, 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2
, phosphoinositide phospholipase C-gamma-2
, phospholipase C-gamma-2
, phosphoinositide phospholipase C
, phospholipase C-IV
, phosphatidylinositol-specific phospholipase C